BioScrip closes acquisition of HomeChoice Partners BioScrip (BIOS) announced the February 1 closing of its previously announced agreement to acquire HomeChoice Partners for $70M in cash. HomeChoice was a majority-owned subsidiary of DaVita (DVA). The purchase price is subject to adjustment pursuant to the terms of the agreement including potential additional consideration based on the results of operations. BioScrip also expects to realize the value of a future tax benefit estimated at $3.9M as a result of the transaction. HomeChoice is expected to generate approximately $70M in annual revenue. Once fully integrated, this business should generate Adjusted EBITDA margins between 12% and 14%. The company estimates that an acquisition of this size can take 9 to 12 months to fully integrate.
News For BIOS;DVA From The Last 14 Days
Check below for free stories on BIOS;DVA the last two weeks.